June 17th 2025
Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.
Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
2nd Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer
View More
What Would CMS Proposed Coverage Decision for Next-Generation Sequencing Mean for Oncologists?
February 16th 2018The day when oncologists can order a Medicare-covered next-generation sequencing diagnostic test may be near at hand, but once this change goes into effect, will oncologists be limited to certain tests, labs, and cancer settings? The answer is unclear.
Read More
Clinical Urology Practices Should Include More Genomic Screening for Prostate Cancer
December 28th 2017With genetic screening for mutations and biomarkers gaining more prevalence in diagnosing and treating cancer, genetic testing and counseling for patients with prostate cancer is becoming a pressing concept that urologists need to better understand. At the 2017 LUGPA Annual Meeting, Leonard Gomella, MD, gave a presentation stressing the importance of integrating genetic testing into clinical practice.
Read More
When to Order Next-Generation Sequencing for a Patient With Metastatic Colon Cancer
December 22nd 2017John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses when to order next-generation sequencing for a patient with metastatic colon cancer.
Watch
Breast Cancer Genome to Shape Precision Medicine
September 16th 2017As the breast cancer genome continues to be unraveled, a host of new targetable alterations outside of HER2 and the estrogen receptor are beginning to emerge, providing the exciting potential for development of new therapies.
Read More
Expert Sees Molecular Genetics Increasingly Integrated into Clinical Decision Making in MPNs
September 16th 2017Advancements made in the field of molecular genetics for patients with myeloproliferative neoplasms may be increasingly incorporated into treatment decisions, according to a presentation by Ann Mullally, MD, during the 2017 SOHO Annual Meeting.
Read More
ProfiLER Study Demonstrates Importance of Genomic Testing for Precision Medicine
June 4th 2017Comprehensive genomic testing is not yet widespread, but a French study presented at the 2017 ASCO Annual Meeting suggested that DNA profiling can be of important value in advancing personalized medicine. Patients who received molecularly targeted agents based on genomic profiles had longer 3-year and 5-year overall survival than those who did not.
Read More
Expert Explains the Importance of Genetic Testing for Patients With Ovarian Cancer
March 14th 2017During the Society for Gynecologic Oncology 48th Annual Meeting in National Harbor, Maryland, Jubilee Brown, MD, offered advice on where to access this counseling and why it is so important for women with ovarian cancer to advocate for genetic testing.
Read More
Molecular Profiling on the Uptake for Increased Targeted Therapies in Bladder Cancer
November 3rd 2016The recommendation for molecular testing made in the second revision of the 2016 guidelines on bladder cancer from the National Comprehensive Cancer Network (NCCN) could make a considerable difference in increasing the amount of trials and targeted therapies in the long run for subtypes of patients with bladder cancer.
Read More
Novel TKI Examined in Metastatic Breast Cancer Patients with HER2 Mutation
June 8th 2016Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.
Read More